Christina Morganti

Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab

Abstract Summary Osteoporosis treatment does not normalize BMD. We hypothesized cyclic romosozumab dosing might provide greater BMD increases. Cyclic therapy (six romosozumab monthly doses then one denosumab dose) produced broadly similar BMD increases as previously reported for...